Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

459.57 +2.54 (+0.56%)
Streaming Delayed Price Updated: 11:01 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months. 
Via Benzinga
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Via The Motley Fool
Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK... 
Via Talk Markets
Topics Stocks / Equities
3 No-Brainer Stocks to Buy on the Latest Sell-Off
Via The Motley Fool
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients. 
Via Benzinga
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings. 
Via Benzinga
Topics Economy
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Via The Motley Fool
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock. 
Via Investor's Business Daily
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions. 
Via Benzinga
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain
The company says there was variability among placebo responses at various sites. 
Via Investor's Business Daily
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals' drug reduced back pain significantly. 
Via Investor's Business Daily
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Unstoppable Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.